

**Current Non-Oncology Clinical Research Trials**

<b>IRB #</b>	<b>Study Title</b>	<b>PI</b>	<b>Sponsor</b>
678	CF Registry	Amaro, Rodolfo	CFF
872	Bronchiectasis Registry	McShane, PJ	COPD Foundation
953	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency	Devine, Megan	Grifols
1030	Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease	Phillely, Julie	OHSU
1032	Liposomal Amikacin for Inhalation for the Treatment of Nontuberculous Mycobacterium	Phillely, Julie	Insmed
1037	Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections	Phillely, Julie	Novartis
1090	Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa) - A Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of Alvelestat (MPH996) in alpha-1 antitrypsin deficiency	Devine, Megan	Mereo
1099	Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population	Phillely, Julie	Electromed
1102	A Phase 1b/2, Open-Label Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma	Lee, Arielle	Aveo
1105	Evaluation of HFCWO using The Vest System® for Treatment of Non-Cystic Fibrosis Bronchiectasis in the home setting	Phillely, Julie	HillRom
1116	BRONCH Study (Bronchiectasis Results Of Natural Clinical History)	McShane, PJ	UTHSCT
1120	Qualitative Development and Psychometric Validation of a Clinical Outcome Assessment (COA) Tool for Bronchiectasis	Phillely/Mcshane	Insmed
1128	Saliva testing for COVID-19 verification of performance	Yost, Janine	PHLET

2020-052	<b>ASPEN</b> - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis	McShane, PJ	Insmmed
2020-061	Study of RHB-204 for the Treatment of Pulmonary Mycobacterium avium Complex (MAC) Disease in Adults with Nodular Bronchiectasis (Clear-MAC Trial)	McShane, PJ	Redhill Biopharma
2020-062	<b>SIMPLIFY</b> - A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy	Couch, Leslie	CFF
2021-002	<b>ENCORE 416</b> - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)	Philly, Julie	Insmmed
2021-005	<b>ARISE 415</b> - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)	Philly, Julie	Insmmed
2021-009	<b>AR-501-001</b> - A Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of the safety and pharmacokinetics of AR-501 (gallium citrate), administered via inhalation, in healthy adult and <i>P. aeruginosa</i> infected cystic fibrosis subjects	Couch, LEslie	Aridis
2021-019	<b>EVA-29879-01</b> - Qualitative Interviews to Inform Clinical Outcome Assessment (COA) Strategy and Measurement(s) in Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease caused by Mycobacterium avium Complex (MAC)	Philly, Julie	AN2 Therapeutics

2021-020	<b>ACTIV-4C</b> - COVID-19 Post-Hospital Thrombosis Prevention Trial: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge	Nwasuruba, Chiagozie	NIH
2021-026	<b>PTK0796-NTM-20203</b> - A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by <i>Mycobacterium abscessus</i> complex (MABc)	Philly, Julie	Paratek
2021-038	<b>ACTIV-1</b> - Randomized Master Protocol for Immune Modulators for Treating COVID-19	Devine, Megan	NCATS
2021-040	A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Participants with Moderate to Severe Asthma (VECTOR)	Amaro, Rodolfo	Astra Zeneca
2021-052	<b>INS1007-211</b> - A single-blind, placebo-controlled, parallel-group study to assess the safety, tolerability and pharmacokinetics of brensocatib administered once daily for 4 weeks in subjects with cystic fibrosis	Amaro, Rodolfo	Insmmed